Trace Biosciences files Form D covering $16.2 million equity offering
The Delaware biotech, based in Beaverton, Oregon, disclosed it has sold about half of a planned equity raise from 19 investors.
Trace Biosciences Inc. filed a Form D with the Securities and Exchange Commission disclosing a new notice of exempt securities offering. The filing lists the date of first sale as 2026-07-28.1 The company is incorporated in Delaware and was formed in 2021.1 Its principal place of business is listed at 1800 NW 167th Place, Suite 160, in Beaverton, Oregon.1
The offering covers equity securities. The filing checks equity as the type of security offered.1 The company claimed the Rule 506(b) exemption under Regulation D.1 The issuer indicated it does not intend the offering to last more than one year.1
On the financial terms, the total offering amount was listed at $16,234,498, with $8,334,499 already sold and $7,899,999 remaining to be sold.1 The filing states 19 investors have already invested in the offering.1 The minimum investment accepted from any outside investor was listed as $0.1 The filing lists $0 in sales commissions and $0 in finders' fees.1
The filing states the offering is not tied to a business combination. In response to the question of whether the offering is being made in connection with a "business combination transaction, such as a merger, acquisition or exchange offer," the company marked "No."1
The related persons named in the filing include Connor Barth, Summer Gibbs, and Lei Wang, each listed as executive officer and director, along with Jonathan Sorger, listed as director.1 Barth signed the filing as Chief Executive Officer on 2026-08-12.1 The industry group is listed as biotechnology within health care.1
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.